Advertisement
LEXINGTON, Ky.--(BUSINESS WIRE)--MedPro Safety Products, Inc. (OTCBB: MPSP), a leading developer of transformational technologies that enable safer medication delivery and blood collection, today announced that it has passed its ISO 13485 recertification audit. The ISO 13485 standard represents the requirements for a comprehensive management system for the design and manufacture of medical devices.

"The recertification is a testament to MedPros commitment to quality," said W. Craig Turner, Chairman and CEO of MedPro Safety Products. "We place the highest priority on ensuring our quality management system complies with the ISO Medical Device standard, FDA regulations and the Medical Device Directive. During this recertification process, we expanded the scope of the certificate to include the design and manufacture of fluid delivery devices. The updated scope reflected our expanding portfolio which will allow MedPro to further address three compelling, yet unmet needs in the market: clinician safety, patient safety and community safety."

MedPros renewed certificate was awarded by BSI Group, a leading global independent business services organization providing standard-based assessments, certifications and solutions. The certification is effective until October 15, 2014.

About MedPro Safety Products, Inc.

Headquartered in Lexington, Kentucky, MedPro Safety Products, Inc. is a leading developer of safer medication delivery and blood collection systems. The Company licenses, develops and manufactures transformational technologies marketed through its global medical device partners. MedPros products address multiple product categories within the medication delivery (injection and infusion) and blood collection (blood collection sets and blood tube holders) markets. Unlike competitive products currently available on the market, MedPros products incorporate safety features that operate without user activation, and therefore require little or no clinician training to use. The total global market opportunity for safer medication delivery and blood collection products is believed to be more than $6 billion. For additional information, please refer to the ‘Investor Relations link on the Companys website (www.medprosafety.com).

Advertisement
Advertisement